Avid Bioservices Inc (CDMO)

[north40000]

CP, you suggest:

"So at a higher level, between full pipeline which is too high and condition specific which is too low, one could partner geographically and FIELD based."

You then list the fields. IMO, your fields are too broad. I would suggest not only specific geographic area where licensee has extant marketing potential but also indication[more specific than your broad field of use] where licensee has extant experience as well with its therapy medium. Where the licensee has a particular immunotherapy drug/biologic experience, limit the licensed use to the combination of Bavi [and maybe its derivatives/2nd generation] with the particular therapy the licensee is then working with.

Subsequent licenses may be put in place as necessary as new entities, products develop. I see no point to giving a licensee market power over something it is not currently working with. To do otherwise would not foster competition among licensees, quite apart from efficacy of respective treatments.